Home › Funds › Ikarian Capital, LLC › RCUS
Ikarian Capital, LLC position in RCUS
ARCUS BIOSCIENCES INC · Health Care
Ikarian Capital, LLC reported holding 734,559 shares of RCUS (ARCUS BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$19.0M, representing 2.79% of its reported portfolio and ranking #4 among its reported holdings. Ikarian Capital, LLC has disclosed RCUS holdings in 9 of the last 13 reported quarters, going back to Q3 2023.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Ikarian Capital, LLC's RCUS position evolved
Ikarian Capital, LLC first disclosed a stake in RCUS in Q3 2023 at 254,876 shares (US$4.6M). The position peaked in Q3 2026 at 734,559 shares, worth US$19.0M. Across 9 filings, Ikarian Capital, LLC increased the stake 4 time(s), trimmed it 1 time(s) and left it unchanged 1 time(s). The most recent filing (Q3 2026) shows 734,559 shares valued at US$19.0M — an increase of 230,000 shares quarter over quarter.. Notable position changes include a 57% increase in Q4 2023 (shares fell 1% over the following quarter), a 46% increase in Q3 2026 (shares fell 35% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2023 | 254.88K | $4.58M | New |
| Q4 2023 | 400.00K | $7.64M | Add |
| Q2 2024 | 145.00K | $2.21M | New |
| Q3 2024 | 113.70K | $1.74M | Reduce |
| Q4 2024 | 141.00K | $2.10M | Add |
| Q1 2025 | 163.36K | $1.28M | Add |
| Q2 2025 | 163.36K | $1.33M | Hold |
| Q2 2026 | 504.56K | $15.56M | New |
| Q3 2026 | 734.56K | $18.97M | Add |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About RCUS and 13F data
RCUS (ARCUS BIOSCIENCES INC) is a Health Care company. 41 other funds we track also report a position in RCUS — the largest reported positions include GILEAD SCIENCES, INC. (US$811.7M), Siren, L.L.C. (US$62.5M), SAMLYN CAPITAL, LLC (US$36.0M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RCUS
- GILEAD SCIENCES, INC. 31.42M sh · $811.70M · Q3 2026
- Siren, L.L.C. 2.42M sh · $62.52M · Q3 2026
- SAMLYN CAPITAL, LLC 1.39M sh · $36.03M · Q3 2026
- Vestal Point Capital, LP 1.30M sh · $33.58M · Q3 2026
- Soleus Capital Management, L.P. 862.00K sh · $22.27M · Q3 2026
- BAKER BROS. ADVISORS LP 844.82K sh · $21.82M · Q3 2026
- Parkman Healthcare Partners LLC 675.52K sh · $17.45M · Q3 2026
- Sofinnova Investments, Inc. 626.18K sh · $16.17M · Q3 2026
- First Turn Management, LLC 577.69K sh · $14.92M · Q3 2026
- Logos Global Management LP 500.00K sh · $12.91M · Q3 2026
More on Ikarian Capital, LLC
FAQ
How long has Ikarian Capital, LLC held RCUS?
Ikarian Capital, LLC has disclosed RCUS holdings in 9 of the last 13 reported quarters, going back to Q3 2023.
What is Ikarian Capital, LLC's current position in RCUS?
As of Q3 2026, Ikarian Capital, LLC holds 734.56K shares of RCUS (ARCUS BIOSCIENCES INC), valued at $18.97M, representing 2.79% of its reported portfolio and ranking #4.
Has Ikarian Capital, LLC been buying or selling RCUS?
In the latest 13F filing (Q3 2026), Ikarian Capital, LLC increased its position in RCUS. The position peaked in Q3 2026 at 734.56K shares.
Which other funds hold RCUS?
Other major institutional holders of RCUS include GILEAD SCIENCES, INC., Siren, L.L.C., SAMLYN CAPITAL, LLC, among 41 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.